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Condensation and short version of title 
 
Condensation:  
The tocolytic potency of MgSO4 is reduced by oxytocin but is reversible by an oxytocin 
receptor antagonist and is equal in twin and singleton myometrium.  
 
Short version of the article title:  
Combination tocolysis in vitro involving MgSO4 and atosiban  
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Abstract 
Background: Preterm birth before 37 weeks’ gestation is the most common and costly 
complication of pregnancy and remains the leading cause of neonatal morbidity, mortality 
and reduced achievement in surviving infants. Magnesium sulfate is one class of tocolytics 
for threatened preterm labor however its clinical efficacy has been questioned.  Twin 
pregnancies are at increased risk of preterm delivery compared to singleton gestations, 
suggesting there is twin-specific risk to preterm delivery in twins. The prevention strategies 
applied to singleton pregnancies however have not been shown to be effective in twin 
pregnancies.   
Objective(s):  To compare the relaxant effect of magnesium sulfate (MgSO4) on spontaneous 
and oxytocin–augmented contractions of human myometrium from singleton and twin 
pregnancies and examine whether the effect of oxytocin on MgSO4’s potency could be 
reversed using the oxytocin receptor antagonist, atosiban.  
Study Design:  Myometrium was obtained at the time of pre-labor cesarean section (36-40 
weeks gestation) from women with singleton (n=23) or twin (n=12) pregnancy. Isometric 
tension recordings were made on myometrial strips mounted in organ baths superfused with 
physiological saline. Strips were exposed to rising concentrations of MgSO4 and the effect on 
spontaneous contractions or stimulated with oxytocin (0.5nmol/L) and in the presence or 
absence of atosiban (100nmol/L) was recorded.  The contractile characteristics after each 
application of MgSO4, including amplitude of contraction and activity integral, were 
measured. Concentration-response curves were fitted using non-linear regression and 
comparison of the -logIC50 values.   
Results: MgSO4 exerted an equal concentration-dependent inhibitory effect on spontaneous 
myometrial contractions from both singleton and twin myometrium (P>0.05).  The 
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application of oxytocin produced a significant rightward shift in the concentration-response 
curves (P<0.001) but no differences were found between pregnancy groups (P>0.05). The 
addition of atosiban shifted concentration-response curves significantly back to the left for 
amplitude of contraction and activity integral in singletons (P<0.001). However, only activity 
integral was significantly reversed in twins (P<0.0001). 
Conclusion(s):  MgSO4 is equipotent in suppressing contractions in singleton and twin 
myometrium. Oxytocin (0.5nmol/L) significantly reduces the tocolytic potency of MgSO4 
which may explain in part, MgSO4’s poor efficacy in vivo but this can be partially reversed 
using an oxytocin receptor antagonist. Combination tocolysis involving oxytocin receptor 
antagonists requires further investigation.   
 
Keywords:  atosiban, contraction, magnesium sulfate, MgSO4, myometrium, oxytocin, 
oxytocin receptor antagonist, pregnancy, tocolysis, twins, uterus  
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Introduction  
Preterm birth (delivery <37 weeks’ gestation) is the leading cause of perinatal morbidity and 
mortality. The majority of cases of preterm birth result from spontaneous preterm labor onset 
involving premature uterine contractions or premature rupture of the membranes.
1
 A number 
of pharmacological agents have been advocated as suppressants of uterine contractions 
(tocolytics) including Magnesium sulfate (MgSO4).   
In vitro, magnesium (Mg) is known to relax smooth muscle and studies in myometrium have 
also found it to significantly decrease both spontaneous and induced (e.g. with oxytocin) 
uterine contractions.
2-5
  However despite these clear laboratory findings, few clinical trials 
have found MgSO4 tocolysis in vivo to be effective in preventing preterm birth or reducing 
newborn morbidities or mortality when compared with an alternative or no tocolytic 
(placebo) treatment.
1, 6
 This lack of efficacy has led the obstetric community to question  its 
use as a tocolytic.
7
 The American College of Obstetricians and Gynecologists and the Society 
for Maternal-Fetal Medicine limit their  support for the use of MgSO4 for ‘short-term 
prolongation of pregnancy (up to 48 hours) to allow for the administration of antenatal 
corticosteroids in pregnant women who are at risk of preterm delivery within 7 days’.8  
 
In vitro studies have shown the concentration of Mg required to abolish spontaneous 
contractions to be around 2-3mmol/L but concentrations required to inhibit oxytocin-
augmented contractions were much greater (around 8-10mmol/L) which is much higher than 
that reported to be safe therapeutically
5, 9
. We therefore questioned: Could we use an oxytocin 
receptor antagonist to increase the tocolytic potential of MgSO4 by removing the negative 
influence of oxytocin on Mg’s potency?  
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Multiple pregnancies e.g. twins, are especially confounded by higher rates of preterm birth 
with ~50–60% of twins reported to deliver preterm compared to ~11%  of singletons,10, 11 
suggesting there is a twin-specific risk to preterm delivery. The preterm birth prevention 
strategies applied to singleton pregnancies have not been found to be effective in twin 
pregnancies
12
 and the evidence for the use of tocolysis in twins is limited. 
The aims of this study were therefore to investigate 1) the inhibitory effect of MgSO4 on 
spontaneous and oxytocin-augmented contractions on strips of human myometrium in our ex 
vivo model, 2) to examine for differences in the potency of MgSO4 between myometrium 
from singleton and twin pregnancies and 3) whether the effects of oxytocin could be reversed 
or reduced with the use of the oxytocin-receptor antagonist, atosiban.  
 
Materials and Methods 
Sample collection and preparation 
Myometrial tissue was obtained with written informed consent from 35 women undergoing 
elective, pre-labor Caesarean section (CS).
13
 All women were between 23 and 43 years of 
age, with a singleton (n=23) or twin (n=12) pregnancy, between 36–40 weeks of gestation. 
Full details of the demographics for all women according to pregnancy group (singleton or 
twin) are given in Table 1. As expected the median length of gestation was significantly 
shorter and birth weight (combined in the case of twins) was significantly higher in the twin 
group (P<0.001).  Local Research Ethics committee (Liverpool East, REC Ref 10/H1002/49) 
and institutional review boards of the Research and Development department, Liverpool 
Women’s Hospital and University of Liverpool approved the study.  
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At operation, myometrial tissue was excised from the upper lip of the lower uterine incision 
site following delivery of the baby and placenta.
14
  Samples were used immediately or within 
12 hours of collection with storage at 4°C.  In the laboratory, multiple strips (5mm x 2mm x 
1mm) were dissected along the direction of longitudinal fibres, as previously described.
15
 
Strips were attached to aluminium clips and placed in 1mL organ baths continually 
superfused with physiological saline (PSS, in mmol/L: 154 NaCl, 5.6 KCl, 1.2 MgSO4, 7.8 
glucose, 10.9 HEPES and 2.0 CaCl2) at a rate of 1.5ml/min, pH 7.4 at 36°C.  One end was 
attached to a fixed hook and the other to a FORT 10g force transducer (World Precision 
Instruments, UK).  Each sample was subjected to 2mN stretch and left to equilibrate in PSS 
until spontaneous contractions were established, typically within 2 hours.
16
  Contractions 
were recorded at a sampling rate of 10Hz via a data acquisition system running the associated 
software (Labscribe 2, WPI UK). 
 
Experimental approach 
The experimental methods were based upon our previous studies of tocolytic potency in 
myometrium.
13
  For spontaneous contractions, strips were left to equilibrate for 1 hour after 
their onset or until a minimum of 4 consecutive contractions of equal amplitude and regular 
frequency were achieved. For oxytocin–induced contractions, strips were allowed to 
equilibrate then contractions were stimulated with oxytocin (0.5nmol/L) for a minimum of 45 
minutes to achieve a stable baseline activity as previously described.
13
  Strips were then 
exposed to rising concentrations of either MgSO4 alone or in combination with atosiban 
(100nmol/L).  
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Each concentration of MgSO4 was added at 20-25 minute intervals based upon previous data 
showing that maximal response to MgSO4 is achieved at 20 minutes.
3, 5
  Measurement of 
contractile activity was performed by calculation of the integral area under the tension curve 
in unit time referred to as ‘activity integral’ or AUC (arbitrary units) and mean maximum 
peak amplitude of contraction (expressed in mN) as previously described.
13, 17
  We have 
previously shown that spontaneous contractions remain stable for over 3 hours of recording 
without significant decrease in amplitude or area under the curve during the time equivalent 
of experimental manoeuvres.
13
 Control activity was taken as the contractile activity in the 
final 20-25 minutes (preceding the first concentration of MgSO4). The effects of MgSO4 
during the final 20 minutes of its 25 minute exposure at each concentration, (allowing for 5 
minutes of  turn-over in the tissue bath) were calculated and expressed as a percentage of the 
integral and amplitude during the control period (i.e. control activity is equal to 100%).   
 
Statistical analysis  
Concentration-response curves were fitted to the logistic equation using non-linear regression 
(PRISM 5.0, Graph Pad Software Inc., San Diego, Ca. USA). The mean half-maximal 
inhibitory concentration of MgSO4 which is the concentration of MgSO4 required to cause a 
50% reduction in activity (IC50) was calculated to examine its inhibitory effects on 
contraction amplitude and activity integral. To compare the effect of MgSO4 between the 
different experimental conditions or patient groups, the negative logarithm of the IC50 (-
logIC50) values were taken and compared on the basis of the F test for the extra sum of 
squares principle.  Unless stated otherwise, all values represent the mean ± standard error of 
the mean (SEM) where ‘‘n’’ is the number of samples and each representing a different 
woman. P < 0.05 was taken as level of significance.  
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Results 
The application of MgSO4 resulted in a dose-dependent decrease in both spontaneous 
contraction amplitude and activity integral in all samples tested (n=14: singleton n=8, twin= 
6, Figure 1).  For most samples (10/14), spontaneous contractions were abolished at a 
concentration of 3.2mM MgSO4 or less. Upon returning to normal PSS (1.2mM MgSO4), 
contractions recovered.  The IC50 for MgSO4 on spontaneous contraction amplitude was 
2.18mM (± 0.024) and activity integral was 1.80mM (± 0.014).  Concentration-response 
curves for MgSO4 on spontaneous contractions according to pregnancy group (singletons or 
twins) are shown in Figure 1B and C and the associated IC50 values are given in Table 2. As 
shown, the potency of MgSO4 on spontaneous contraction amplitude and activity integral was 
equal in strips from both singleton and twin myometrium (P>0.05).   
The concentration of MgSO4 required to abolish contractions was significantly increased in 
the presence of oxytocin compared to spontaneous conditions (P<0.0001, amplitude and 
activity integral). In a number of cases contractions persisted even at 12mM MgSO4 which is 
10x the concentration in our PSS i.e. control concentration. Concentration-response curves 
for MgSO4 in the presence and absence of oxytocin are shown in Figure 2A and B. The IC50 
for MgSO4 under oxytocin was 8.13mM (± 0.066) for amplitude of contraction and 5.77mM 
± (0.033) for activity integral  (n=14, combined data; n=8 singletons, n=6 twins).  When 
stratified according to pregnancy group, there was no difference in the potency of MgSO4 
between singleton and twin myometrium on oxytocin-augmented contractions (Figure 2C 
and D and Table 2).  
In an effort to reverse the effect of oxytocin on MgSO4’s potency, the effect of increasing 
concentrations of MgSO4 on oxytocin-augmented contraction (as performed above) was 
examined in paired strips in the presence and absence of atosiban (100nmol/L, based on our 
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previous study).
13
 Representative traces are shown in Figure 3 (A and B), as well as 
appropriate time controls for atosiban alone and oxytocin alone (Figure 3C and D).  As 
shown previously
13
 contractions persisted for a number of hours in the presence of oxytocin 
without significant decrease in in amplitude or AUC. Similarly, the application of atosiban 
(100nmol/L) alone resulted in an initial decrease in force which the remained stable for the 
remainder of the experiment (n=12).   
The combination of MgSO4 plus atosiban significantly shifted the concentration-response 
curve to the left compared to MgSO4 alone (paired strips).  This was true for both amplitude 
of contraction and activity integral (Figure 4A and B). Consequently, the IC50 values for the 
combination of MgSO4 plus atosiban were significantly lower: The IC50 values for amplitude 
of contraction for MgSO4 plus atosiban being 5.01mM (±0.142) compared to 8.59mM (± 
0.226) for MgSO4 alone (P<0.0001) and for AUC, MgSO4 plus atosiban was  2.81mM 
compared to 4.74 ± 0.011 for MgSO4 alone (P<0.0001).  
When stratified according to pregnancy group, the curves for both amplitude of contraction 
and activity integral were shifted significantly to the left in the singleton pregnancy group, 
with significantly lower IC50 values reported in the presence of atosiban (P<0.0001, Figure 
4C and D and Table 3). For the twin myometrial group however, only the concentration-
response curve for activity integral was significantly shifted to the left (P=0.0045). There was 
a small but non-significant shift to the concentration-response curve for amplitude of 
contraction (P=0.1829) (Figure4 E and F and Table 3).  
 
Comment 
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Magnesium sulfate has been one of the commonly used tocolytic agents for nearly 40 years
18
 
and has been the subject of a number of clinical trials evaluating its efficacy (see
1, 6
 for 
reviews).  Our data extends the in vitro findings confirming Mg’s ability to reduce 
myometrial contractions. The most recent Cochrane Review of tocolysis using MgSO4 for 
preterm labor however, found that it ‘is ineffective at delaying birth or preventing preterm 
birth’.6 To help understand why this discrepancy between in vitro and in vivo findings occurs, 
we examined the effect of MgSO4 on both spontaneous and oxytocin-augmented contractions 
as well as the combined effect of MgSO4 and the oxytocin receptor antagonist atosiban. 
We found that a relatively modest increase in MgSO4 from 1.2 (control) to 3.2mmol/M would 
abolish spontaneous contractions in 70% of samples. This value is very close to the 
3.0mmol/L reported by Tica et al., (2007) despite the differences in sample preparation and 
experimental conditions which included Mg-free PSS as control. The therapeutic 
concentration for tocolysis (2-3 mmol/L) is also within this range.
9, 19
    
The cation of magnesium (Mg
2+
) is thought to be responsible for its tocolytic effect as 
magnesium chloride (MgCl2) also displays similar relaxant effects in myometrium.  Mg is 
suggested to act via cationic competition with Ca
2+
 and blocking (L-type) channel-dependent 
Ca influx, thereby decreasing intracellular Ca availability for contraction as well as reducing 
agonist-stimulated Ca release from intracellular stores e.g. the sarcoplasmic reticulum.
4
  The 
ability of Mg’s action to be reversed upon washout and with the application of the L-type Ca 
channel agonist BayK8644 supports this, as does clinical data which shows that calcium 
supplementation in hypocalcaemic women after receiving MgSO4 causes increased uterine 
activity.
19
 
In the presence of oxytocin the tocolytic effect of MgSO4 was significantly reduced with IC50 
values being shifted significantly to the right, confirming that a significantly greater (>4 
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times) concentration of Mg is required to inhibit oxytocin-augmented contractions
3, 5
 which is 
a concentration that would not be considered safe.
9
 In an earlier study, Tica et al., saw a 30-
40% decrease in activity at ≥8mmol/L MgSO4 in the presence of oxytocin. Here, a 50% 
reduction in contraction amplitude was achieved around 8mmol/L MgSO4 but abolition of 
contraction under oxytocin was not achieved until ≥12mmol/L. Thus this study is in 
agreement with those previously showing that Mg at therapeutic concentrations (2-3mmol/L) 
is only effective at inhibiting spontaneous myometrial contractions and not those where 
oxytocin is present.
5
  
We also compared the effect of MgSO4 in singleton and twin pregnancies as the strategies 
used to prevent preterm birth in singletons have not been found to be effective in twin 
pregnancies.
12
 We may hypothesise that the additional stretch placed on the uterus at an 
earlier time point in gestation, owing to two fetuses, as well as endocrine differences (e.g. 
two placentas/membranes), may lead to an increased drive on the uterus towards labor onset 
in twins, including changes in gene expression which could ultimately affect its contractility 
and response to tocolytics. Our earlier in vitro data on tocolytic potency in the presence of 
oxytocin in twins supports this.
13
 However, here we found no difference in the potency of 
MgSO4 between the two tissue types, suggesting that despite the potential for any differences 
between tissues, MgSO4 acts in a similar manner and is equipotent in both groups. 
Oxytocin’s actions in myometrium are multiple but are primarily thought to involve increased 
Ca entry via L-type channels, reduced Ca exit and the release of Ca from the SR.
20
 Thus the 
actions of oxytocin are in opposition to Mg and would therefore explain, in part, the 
increased concentration of Mg required to inhibit contractions augmented by oxytocin. We 
used oxytocin in our study to mimic the hormonal situation surrounding labor.  That the 
effects of oxytocin in our assay are evident at a relatively low concentration emphasises the 
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significant negative effect of oxytocin on Mg’s potency and adds insight into why MgSO4’s 
tocolytic effect in vivo has been disappointing. 
Our previous studies showed that twin pregnancy myometrium responded more greatly to 
oxytocin stimulation
17
 which may indicate a change in the number of oxytocin receptors 
expressed.  We also noted a reduction in the potency of both indomethacin and progesterone 
to suppress oxytocin-augmented contractions in twins compared to singletons.
13
 Thus it was 
somewhat surprising that we did not detect any differences in the potency of MgSO4 in 
inhibiting oxytocin-induced contractions between the two groups. 
The addition of the oxytocin-receptor antagonist, atosiban resulted in a partial reversal of the 
effect of oxytocin on MgSO4’s potency in that the IC50 for MgSO4 in the presence of atosiban 
was shifted significantly back to the left compared to MgSO4 alone. This is an important 
point of interest as it could mean that a combination approach to tocolysis involving anti-
oxytocins may be beneficial for improving tocolytic efficacy in vivo. In a recent study, we 
also found other tocolytic agents and suppressants of uterine activity to be less effective in 
the presence of oxytocin, including indomethacin and the acute application of progesterone.
13
  
Thus these findings may be extendable to other tocolytic agents.  Indeed, the combination of 
atosiban with the calcium channel blocker nifedipine in vitro, has been shown to exert an 
additive tocolytic effect on the contractility of myometrial strips in both pre-term and term 
women 
21
 whilst a combination of atosiban plus ritodrine was found to cause a synergistic 
inhibition of myometrial activity in pregnant rat myometrium.
22
   
 
The idea of combination tocolytics or dual agent primary therapy to inhibit preterm labor 
contractions in vivo has been explored previously including trials of MgSO4 administered 
with beta-mimetic agonists e.g. ritodrine or terbutaline.
23-28
 The rationale being that as each 
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agent has a different mechanism of action, there may be some additive effects that inhibit 
uterine contractions, thus increase the efficacy of tocolysis and hence prolong gestation.  
However, whilst combined treatment may improve tocolytic efficacy, it may also produce an 
increase in serious maternal side effects and so should be addressed with caution. This is 
particularly the case if combinations of agents used have similar sites of action e.g. both 
nifedipine and Mg target L-type calcium channels which are distributed throughout other 
smooth muscles and cardiac muscle. Outcomes from a  recent Cochrane review of trials 
involving combination tocolytic use for inhibition of preterm labor found that there was 
insufficient evidence to show whether combination tocolytic approaches were more or less 
effective than a standard single tocolytic drug, or if they have more adverse events.
29
 They 
also reported a lack of combination trials involving the most widely used tocolytics such as 
atosiban or nifedipine.  
It should be noted that the IC50 values in the presence of atosiban did not mirror those in 
oxytocin –free conditions, suggesting that the effect of oxytocin was not completely reversed 
using this concentration of atosiban. In our study of twin myometrium, whilst amplitude of 
contraction appeared to be reduced in the presence of atosiban, only activity integral was 
significantly reduced in the presence of atosiban compared to Mg alone.    Reasons for this 
difference are not known but may reflect the small sample size in our twin group which is a 
limitation of  the study.  
An additional limitation is that we did not include samples from women in labor or gestations 
before 36
+4
 weeks as many women laboring pre-term deliver vaginally. Hence it would be 
interesting to see if similar results would be obtained in these more clinically relevant tissues, 
when the uterine environment may be different. 
30
 The use of a homogenous study population 
of non laboring women with term gestation however, provided a well-controlled in vitro 
comparison of the effect of MgSO4 between singleton and twin pregnancy myometrium 
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which is a major advantage of this study. As the frequency of contractions in human 
myometrium is low we had to analysis data over a 20 minute period to ensure there was 
sufficient activity to measure.  This timeframe may however underestimate the effects of 
MgSO4 on amplitude compared to measuring it in the last 5-10 minutes of the application 
when activity had stabilized. Antenatal MgSO4 given to women at risk of preterm birth was 
shown to substantially reduce the risk of cerebral palsy in their children.
31
  Currently, 
pregnant women experiencing threatened preterm birth (less than 30 weeks gestation) are 
therefore given MgSO4.   So whilst MgSO4 is not used for the indication of preterm labor per 
se, and despite the potential for increased risks for maternal or neonatal side effects from dual 
therapy, it is being administered in combination with a tocolytic agent which is likely to be 
atosiban (in UK), indomethacin or nifedipine.  Further studies, both basic and clinical, should 
therefore address these different combinations of agents with MgSO4 on myometrium to 
establish which is most effective, as well as examining for potential harmful side effects of 
dual therapy, especially when the same cellular sites or pathways are targeted. 
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Table 1  Maternal demographics for the study group and according to pregnancy group 
Characteristic 
Combined 
(n=35) 
Singletons 
(n=23) 
Twins 
(n=12) 
Maternal age, years 32 (± 5.2) 32 (± 4.3) 31.5 (± 5.6) 
Maternal BMI 25 [23-29.7] 27.5 [23.4-33.7] 23.8 [22.4-27.0] 
Gestational age, days 273 [264-275] 274 [272-275] 263 [259-264]* 
Birth weight(s), g  3870 [3465-4920] 3690 [3270-3880] 5207 [4388-5817]* 
Parity    
    Para 0 11 (31.4%) 6 (26.1%) 5 (41.7%) 
    Para 1 13 (37.1%) 8 (34.85) 5 (41.7%) 
    Para >1 11 (31.4%) 9 (39.1%) 2 (16.7%) 
Reason for CS    
    Previous CS 18 (51.4%) 17 (73.9%) 1 (8.3%) 
    Previous difficult   
    vaginal delivery 
1 (2.9%) 1 (4.3%) 0 
    Breech 2 (5.7%) 0 2 (16.7%) 
    Fetal Reason 3 (8.6%) 1 (4.3%) 2 (16.7%) 
   Maternal Reason 4 (11.4%) 4 (17.4%) 0 
   Maternal choice 7 (20.0%) 0 7 (58.3%) 
    
 
Abbreviations: BMI, body mass index; CS, caesarean section; IQR, interquartile range; SD, 
standard deviation.   
20 
 
20 
 
Data are presented as mean (+SD), median [IQR], or frequencies (counts, n, and percentages) 
where appropriate. Gestational age and maternal age are age at delivery. The BMI was 
recorded at pregnancy booking. Birth weights are combined in the case of twins. Asterisk  
indicates significantly shorter gestation in twins and significantly greater birth weight in 
twins, Kruskal Wallis Test, P<0.05) 
Previous difficult vaginal delivery refers to shoulder dystocia in previous labor. Fetal reason 
included intra-uterine growth restriction (n=2, twins) and fetal ECG outside normal limits 
(n=1). Maternal reason included previous ectopic pregnancy (n=1), coeliac disease (n=1), 
chronic fatigue syndrome (n=1) and placenta previa (n=1). 
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Table 2 IC50 values of MgSO4 on spontaneous and oxytocin-augmented contractions from 
singleton and twin myometrium. 
 Singleton (n=8) Twin (n=6) P value 
Spontaneous    
Amplitude 2.15mM ± 0.027 2.23mM ± 0.043 0.4676 
AUC 1.84mM ± 0.019 1.79mM ± 0.021 0.5214 
    
OT-augmented    
Amplitude 8.55mM ± 0.208 7.67mM ± 0.305 0.3034 
AUC 5.81mM ± 0.230 5.77mM ± 0.236 0.9462 
    
 
Abbreviations: AUC (activity integral, area under the curve) OT (oxytocin), 
Concentrations were compared by taking the –LogIC50 and the F test extra sum of squares 
principal 
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Table 3 IC50s of MgSO4 in the presence an absence of atosiban (100nM) on oxytocin-
augmented myometrial contractions according to pregnancy group 
 MgSO4 MgSO4 + atosiban 
Combined samples (n=21)   
Amplitude 8.59mM ± 0.226 5.01 ± 0.142*** 
AUC 4.74mM ± 0.011 2.81mM ± 0.053*** 
   
Singletons (n=15)   
Amplitude 8.13mM ± 0.0225 4.28mM ± 0.125*** 
AUC 4.57mM ± 0.114 2.62mM ± 0.050*** 
   
Twins (n=6)   
Amplitude 10.42mM ± 0.781 8.13mM ± 0.399 
AUC 5.33mM ± 0.261 3.43mM ± 0.150** 
   
 
Asterisk indicates a significant difference between the -logIC50 values  in the presence and 
absence of atosiban where *** is  P<0.001, ** is P<0.01 
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Figure legends 
Figure 1.  The effect of MgSO4 on spontaneous contractions in singleton and twin 
myometrium. A representative trace showing the inhibitory effect of increasing 
concentrations of MgSO4 on spontaneous contractions of human myometrium is shown in 
(A).  In most cases (10/14), contractions were inhibited by ≤3.2mM MgSO4.  Note the effect 
was reversible upon washout. (B) and (C) show the concentration response curves for the 
effect of MgSO4 on singleton (blue circles) and twin (red squares) myometrial amplitude and 
activity integral (AUC) respectively. Data are presented as mean (± standard error of the 
mean, SEM) percentage amplitude and AUC before and after the application of MgSO4 
(control). 
 
Figure 2. The effect of oxytocin on MgSO4's potency in human myometrium. (A) and (B) 
show the concentration-response curves for the effect of MgSO4 on contraction amplitude 
and activity integral (AUC) respectively, in the presence (purple squares) and the absence 
(blue circles) of oxytocin (0.5nM). The concentration-response curves for MgSO4 are 
significantly shifted to the right in the presence of oxytocin (P<0.0001). (C) and (D) show the 
concentration-response curves for MgSO4 on contraction amplitude and activity integral 
(AUC) in the presence of oxytocin according to pregnancy group (singleton: blue circles, 
twin: red squares).  MgSO4 is as potent on oxytocin-augmented contractions in twins as it is 
in singletons. Data are presented as mean (± standard error of the mean, SEM) percentage 
amplitude and AUC before and after the application of MgSO4 (control). Asterisk indicates a 
significant difference between the -logIC50 values where *** is  P<0.001, ** is P<0.01 and 
* is P<0.05. 
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Figure 3. The effect of the combination of MgSO4 plus atosiban on oxytocin-augmented 
contractions. Representative recordings (paired strips) showing (A) the effect of increasing 
concentrations of MgSO4 on oxytocin-augmented contractions, (B) the effect of MgSO4 in 
the presence of atosiban (100nM),   (C) atosiban alone (time control) and (D) oxytocin time 
control. Arrows indicate where oxytocin (0.5nM) was added and remained throughout the 
experiment. The addition of atosiban significantly reduced the concentration of MgSO4 at 
which oxytocin-augmented contractions were inhibited; from ≥12mM (A) to ~8mM (B).  
 
Figure 4. The concentration-response curves for the combination of MgSO4 plus 
atosiban on oxytocin-augmented contractions. (A and B) depict the concentration-response 
curves for the effect of MgSO4 on oxytocin-augmented myometrial contractility (amplitude 
of contraction and integral of force, AUC respectively) on all samples (n=21) in the presence 
(green squares) and absence (purple circles) of atosiban (100nM) as well as atosiban time 
control (grey triangles). When stratified according to pregnancy group; (C and D, singleton, 
n=15, E and F twins, n=6) the application of atosiban shifted the concentration curves 
significantly towards the left for both amplitude of contraction and activity integral in 
singleton myometrium, (C and D, P<0.0001). Only activity integral was significantly shifted 
to the left in the twin group (E, P=0.1829 and F, P<0.01). Data are presented as mean (± 
SEM) percentage of amplitude and activity integral (AUC) before the application of MgSO4 
or atosiban (control). Asterisk indicates a significant difference between the -logIC50 values 
where *** is  P<0.001, ** is P<0.01 and * is P<0.05. 
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